This result suggests that inhibition of VEGF alone, at least in some groups of patients with CRC and preexisting anticancer immunity, provides an immunostimulatory effect sufficient to augment the anticancer immune response and provides a rationale to combine bevacizumab with a CPI to amplify immunity (38). Here, VEGFA is linked to colorectal carcinoma.